Pasar al contenido principal

ALLANANDO EL CAMINO HACIA LA PREVENCION: INTERCEPTANDO EL DESARROLLO DE LA LEUCEMIA INFANTIL DE CELULAS B

PID2024-155590OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para la Investigación y el Desarrollo Experimental
Subprograma Subprograma Estatal de Generación de Conocimiento Científico-Técnico y Desarrollo Experimental
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2024
Plan Estatal 2024-2027 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PD-1 Expression Promotes Immune Evasion in B-ALL

  • Casado-García, Ana
  • García-Aguilera, Gonzalo
  • Pozo, Julio
  • Oak, Ninad
  • Barrena, Susana
  • Ruiz-Corzo, Belén
  • Lalchandani, Jaanam
  • Chamorro-Vera, Ana
  • Castillo-Robleda, Ana
  • Soriano, Beatriz
  • Alemán-Arteaga, Silvia
  • Sánchez, Elena G.
  • Martínez-Cano, Jorge
  • López-Álvarez de Neyra, Andrea
  • Somoza-Cotillas, Paula
  • Blanco, Óscar
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • García-Criado, Francisco Javier
  • García-Cenador, Begoña
  • Cobaleda, César
  • Vicente-Dueñas, Carolina
  • Nichols, Kim E.
  • Orfao, Alberto
  • Ramírez‑Orellana, Manuel
  • Sánchez García, Isidro
[Data Availability Statement] The data presented in this study are openly available in to NCBI’s Sequence Read Archive (SRA) under the BioProject accession number PRJNA1084753. This paper does not report original code. Preprints ID: https://doi.org/10.20944/preprints202505.0386.v1., [Data and Code Availability] Authors confirm that all relevant data are included in the paper and/or its supplemental information files. All data reported in this article are deposited to NCBI’s Sequence Read Archive (SRA) under the BioProject accession number PRJNA1084753. This paper does not report original code., [Background/Objectives:] In children developing B-cell acute lymphoblastic leukemia (B-ALL), an immune evasion event takes place where otherwise “silent” preleukemic cells undergo a malignant transformation while escaping immune control, often through unknown mechanisms., [Methods and Results:] Here, we identify the upregulation of PD-1 expression in preleukemic cells, triggered by Pax5 inactivation in mice and correlating with the time of conversion to leukemia, as a novel marker that favors leukemia evasion. This increase in PD-1 expression is apparent across diverse molecular B-ALL subtypes, both in mice and humans. PD-1 is not required for B-cell leukemogenesis, but, in the absence of PD-1, tumor cells express NK cell inhibitory receptors, highlighting the necessity for leukemic cells to evade the host’s NK immune response in order to exit the bone marrow. PD-1 expression reduces natural antitumor immune responses, but it sensitizes leukemic cells to immune checkpoint blockade strategies in mice and humans. PD-1 targeting confers clinical benefits by restoring NK-mediated tumor cell killing in vitro and eliminating tumor cells in vivo in mice engrafted with B-ALL., [Conclusions:] These results identify PD-1 as a new therapeutic target against leukemic progression, providing new opportunities for the treatment and possibly also the prevention of childhood B-ALL., This research was funded by: Research at C. Cobaleda’s laboratory was partially supported by Grant PID2021-122787OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF/EU” and a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-“. Institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO are also acknowledged. Research in C. Vicente-Dueñas group has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI22/00379 and co-funded by the European Union (European Regional Development Fund (ERDF)/European Social Fund (ESF)). K. E. Nichols receives funding from the American Lebanese Syrian Associated Charities (ALSAC); R01CA241452 from the National Cancer Institute; R21AI113490 from the National Institute of Allergy and Infectious Diseases; Histiocytosis Association; and Cures within Reach. MR research is partially supported by Asociación Pablo Ugarte. Research in ISG group is partially supported by Grant PID2021-122185OB-I00 funded by MICIU/AEI/10.13039/501100011033 and PID2024-155590OB-I00 and by “ERDF/EU”, by Junta de Castilla y León (UIC-017, CSI144P20 and CSI016P23), by the Fundación Científica de la Asociación Española contra el Cáncer (TRNSC247893SÁNC) and by Instituto de Salud Carlos III (ISCIII) (AC24/00021). C. Cobaleda, M. Ramírez and I. Sánchez-García have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC) and by the Fundacion Unoentrecienmil (CUNINA project). M. Ramírez and I. Sánchez-García have been supported by the TRANSCAN2023-1858-066–REACTION Project. A. Casado-García was supported by an FSE-Conserjería de Educación de la Junta de Castilla y León 2019 (ESF, European Social Fund) fellowship (CSI067-18) and by Juan de la Cierva 2022 (JDC2022-049078-I). B. Ruiz-Corzo is supported by an FSE-Conserjería de Educación de la Junta de Castilla y León 2022 (ESF, European Social Fund) fellowship (CSI002-22). S. Alemán-Arteaga and A. Lopez-Alvarez de Neyra are supported by an Ayuda para Contratos predoctorales para la formación de doctores (PRE2019-088887) and (PRE2022-103628), respectively. J. Martínez-Cano was supported by a predoctoral fellowship FPI-UAM 2019., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

PD-1 Expression Promotes Immune Evasion in B-ALL

  • Casado-García, Ana
  • García-Aguilera, Gonzalo
  • Pozo, Julio
  • Oak, Ninad
  • Barrena, Susana
  • Ruiz-Corzo, Belén
  • Lalchandani, Jaanam
  • Chamorro-Vera, Ana
  • Castillo-Robleda, Ana
  • Soriano, Beatriz
  • Alemán-Arteaga, Silvia
  • Sánchez, Elena G.
  • Martínez-Cano, Jorge
  • López-Álvarez de Neyra, Andrea
  • Somoza-Cotillas, Paula
  • Blanco, Óscar
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • García-Criado, Francisco Javier
  • García-Cenador, Begoña
  • Cobaleda, César
  • Vicente-Dueñas, Carolina
  • Nichols, Kim E.
  • Orfao, Alberto
  • Ramírez‑Orellana, Manuel
  • Sánchez García, Isidro
In children developing B-cell acute lymphoblastic leukemia (B-ALL), an immune evasion event takes place where otherwise “silent” preleukemic cells undergo a malignant transformation while escaping immune control, often by unknown mechanisms. Here, we identify the upregulation of PD-1 expression in preleukemic cells, triggered by Pax5 inactivation in mice and correlating with the time of conversion to leukemia, as a novel marker that favors leukemia evasion. This increase in PD-1 expression is apparent across diverse molecular B-ALL subtypes, both in mice and humans. PD-1 is not required for B-cell leukemogenesis but in the absence of PD-1, tumor cells express NK cell inhibitory receptors highlighting the necessity for leukemic cells to evade the host's NK immune response in order to exit the bone marrow. PD-1 expression reduces natural anti-tumor immune responses, but it sensitizes leukemic cells to immune checkpoint blockade strategies in mice and humans. PD-1 targeting confers clinical benefit by restoring NK-mediated tumor cell killing in vitro and eliminating tumor cells in vivo in mice engrafted with B-ALL. These results identify PD-1 as a new therapeutic target against leukemic progression, providing new opportunities for the treatment and possibly also the prevention of childhood B-ALL., The authors thank all the members of their laboratories for discussion. We also thank the Public Resource of Patient-derived and Expanded Leukemias (PROPEL), https://propel.stjude.cloud, as provider of leukemia xenografts used in this study and the American Lebanese Syrian Associated Charities of St. Jude Children’s Research Hospital. Research at C. Cobaleda's laboratory was partially supported by Grant PID2021-122787OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and by “ERDF/EU”, and a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-”. Institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO are also acknowledged. Research in C. Vicente-Dueñas group has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI22/00379 and co-funded by the European Union (European Regional Development Fund (ERDF)/European Social Fund (ESF)). K. E. Nichols receives funding from the American Lebanese Syrian Associated Charities (ALSAC); R01CA241452 from the National Cancer Institute; R21AI113490 from the National Institute of Allergy and Infectious Diseases; Histiocytosis Association; and Cures within Reach. MR research is partially supported by Asociación Pablo Ugarte. Research in ISG group is partially supported by Grant PID2021-122185OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and PID2024-155590OB-I00 and by “ERDF/EU”, by Junta de Castilla y León (UIC-017, CSI144P20, and CSI016P23), by the Fundación Científica de la Asociación Española contra el Cáncer (TRNSC247893SÁNC), and by Instituto de Salud Carlos III (ISCIII) (AC24/00021). C. Cobaleda, M. Ramírez, and I. Sánchez-García have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC), and by the Fundacion Unoentrecienmil (CUNINA project). M. Ramírez, and I. Sánchez-García have been supported by the TRANSCAN2023-1858-066 – REACTION Project. A. Casado-García was supported by a FSE-Conserjería de Educación de la Junta de Castilla y León 2019 (ESF, European Social Fund) fellowship (CSI067-18) and by Juan de la Cierva 2022 (JDC2022-049078-I). B. Ruiz-Corzo is supported by a FSE-Conserjería de Educación de la Junta de Castilla y León 2022 (ESF, European Social Fund) fellowship (CSI002-22). S. Alemán-Arteaga and A. Lopez-Alvarez de Neyra are supported by an Ayuda para Contratos predoctorales para la formación de doctores (PRE2019-088887) and (PRE2022-103628), respectively. J. Martínez-Cano was supported by a predoctoral fellowship FPI-UAM 2019. We also thank the Hartwell Center and Dr. Ti-Cheng Chang from the Center for Bioinformatics at SJCRH for their support to the whole genome sequencing and bioinformatic pipelines., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deletion of 9p drives B-ALL through heterozygous inactivation of Pax5 and Cd72 in preleukemic cells

  • Ruiz-Corzo, Belén
  • Casado-García, Ana
  • Oak, Ninad
  • Somoza-Cotillas, Paula
  • López-Álvarez de Neyra, Andrea
  • Martínez-Cano, Jorge
  • Pérez-Pons, Alba
  • Sánchez, Elena G.
  • Blanco, Oscar
  • Blanco, Oscar
  • Alonso-López, Diego
  • De Las Rivas, Javier
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • García Criado, Francisco Javier
  • García Cenador, María Begoña
  • Orfao, Alberto
  • Ramírez-Orellana, Manuel
  • Cobaleda, César
  • Vicente-Dueñas, Carolina
  • Nichols, Kim E.
  • Sánchez-García, Isidro
The contribution of 9p deletion to B cell acute lymphoblastic leukemia (B-ALL) has remained elusive since its discovery more than 40 years ago. Here we show that loss of CD72 is recurrent in B-ALL cases containing PAX5 deletions, and that Cd72 haploinsufficiency drives B-ALL development in Pax5+/- mice. Mechanistically, Cd72+/-;Pax5+/- precursor B cells exhibited an inflammatory transcriptional profile characterized by a decrease in Myd88 expression, a finding that aligns with our previous studies of B-ALL development in Pax5+/- mice following exposure to immune stressors. These combined genomic analyses and functional models provide compelling evidence that co-deletion of 2 contiguous genes, Pax5 and Cd72, drives B cell leukemogenesis., MICIU/AEI/ 10.13039/501100011033 and ERDF/EU grants PID2021-122185OB-I00 and PID2024-155590OB-I00 (to ISG). Junta de Castilla y León grants UIC-017, CSI144P20, and CSI016P23 (to ISG). Fundacion Unoentrecienmil CUNINA2 project (to ISG). Fundación Científica de la Asociación Española contra el Cáncer (TRNSC247893SÁNC) (to ISG). Instituto de Salud Carlos III (ISCIII) (AC24/00021) (to ISG). Fundación Científica de la Asociación Española contra el Cáncer grant PRYCO211305SANC (to CC, MR, and ISG). “La Caixa” Foundation under the project code LCF/PR/HR25/52450048 (to CC, MR, and ISG). TRANSCAN2023-1858-066 – REACTION Project (to MR and ISG). Research at C. Cobaleda’s laboratory was partially supported by Grant PID2021-122787OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and ERDF/EU grant PID2021-122787OB-I00 (to CC). “Fundación Síndrome de Wolf-Hirschhorn o 4p-” research contract (to CC). “Fundación Ramón Areces” and “Banco de Santander” institutional grants to the Centro de Biología Molecular. Instituto de Salud Carlos III (ISCIII) project PI22/00379 (to CVD). American Lebanese Syrian Associated Charities (ALSAC) (to KEN). National Cancer Institute/NIH grant R01CA241452 (to KEN). National Institute of Allergy and Infectious Diseases Histiocytosis Association Cures within Reach grant R21AI113490 (to KEN). Asociación Pablo Ugarte (to MR). FSE-Conserjería de Educación de la Junta de Castilla y León 2019 (ESF, European Social Fund) fellowship CSI067-18 (to ACG). Juan de la Cierva 2022 grant JDC2022-049078-I (to ACG). FSE-Conserjería de Educación de la Junta de Castilla y León 2022 (ESF, European Social Fund) fellowship CSI002-22 (to BRC). Ayuda para Contratos predoctorales para la formación de doctores (PRE2022-103628) (to ALAN). Universidad Autónoma de Madrid predoctoral fellowship FPI-UAM 2019 (to JMC).